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Abstract
Background
Metabolic bone disorders frequently occur in patients with chronic liver disease; however,
the association between liver fibrosis and bone mineral density in patients with non-alcoholic
fatty liver disease (NAFLD) is unclear.
Methods
This is a cross-sectional analysis of 231 asymptomatic subjects (160 women, 61.6 years
old) from a university hospital setting, between February 2012 and December 2014. Bone
mineral density (BMD) was measured at the lumbar spine, femur neck, and total hip using
dual-energy X-ray absorptiometry (DXA). Liver fibrosis and steatosis were assessed using
transient elastography.
Results
Among a total of 231 individuals, 129 subjects (55.8%) had NAFLD. BMDs at lumbar spine,
femur neck, and total hip were significantly lower in patients having NAFLD with significant
fibrosis, compared with patients having NAFLD without significant fibrosis (Ps<0.005). In
patients with NAFLD, significant liver fibrosis revealed marked negative correlations with
BMD at the lumber spine (r = –0.19, P = 0.032), femur neck (r = –0.19, P = 0.034), and total
hip (r = –0.21, P = 0.016). A multivariate linear regression analysis revealed that significant
liver fibrosis was independently correlated with low BMD at the femur neck (β = –0.18,
P = 0.039) and total hip (β = –0.21, P = 0.005) after adjustment for age, sex, BMI, fasting
plasma glucose, alanine aminotransferase, high-density lipoprotein cholesterol, and liver
steatosis among patients with NAFLD. Using multivariable logistic regression, significant
liver fibrosis was independently associated with overall osteopenia and osteoporosis in sub-
jects having NAFLD (OR = 4.10, 95% CI = 1.02–16.45).
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Conclusion
The presence of significant liver fibrosis assessed via TE was independently associated
with low BMD in NAFLD subjects.
Introduction
Non-alcoholic fatty liver disease (NAFLD), one of the most common chronic metabolic liver
disorders, is a major public health problem strongly correlated with growing prevalence of
obesity or diabetes [1]. NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis
(NASH), representing progressive inflammation, which can progress to liver cirrhosis or hepa-
tocellular carcinoma. Oxidative stress, pro-inflammatory cytokines, and lipotoxicity, in con-
junction with various inflammatory reactions and fibrosis, have been found to be related with
an increased risk of NASH and fibrosis progression [2]. Recently, liver fibrosis diagnosed
based on liver biopsy rather than NAFLD activity score (NAS), a histological scoring system
including features of steatosis, lobular inflammation, and hepatocellular ballooning but not
fibrosis, was suggested to be the main crucial prognostic factor for overall and liver-related
mortality in subjects with NAFLD [3,4].
Metabolic bone disease in patients with liver disease, known as hepatic osteodystrophy, is
characterized by poor bone mineralization and loss of bone mass and quality, and its preva-
lence has also rapidly increased [5]. Several studies reported a degree of association between
NAFLD and low bone mineral density (BMD), showing a higher risk of osteoporosis in post-
menopausal women with NAFLD [6]. The association between NAFLD and osteopenia
remains controversial. Furthermore, few studies have investigated whether NAFLD with liver
fibrosis and low BMD are distinctively related to each other and whether significant liver fibro-
sis is an independent determinant of low BMD.
Osteoclasts and osteoblasts execute bone remodeling by resorbing and forming bone
respectively, and physiological bone remodeling is tightly regulated by osteocytes. Multiple
mediators, including oncofetal fibronectin, insulin-like growth factor-1 (IGF-1), the receptor
activator of the nuclear factor kappa B ligand/osteoprotegerin (RANKL/OPG) pathway, and
several inflammatory cytokines (e.g. tumor necrosis factor [TNF]-α, interleukin-6 [IL-6], and
IL-17), are commonly involved in the process of bone loss by affecting the above cells and
inducing an imbalance between bone formation and bone resorption in patients with liver dis-
ease [7–9]. In line with this, we hypothesized that progressive liver fibrosis in NAFLD indicat-
ing severe inflammatory status is associated with low BMD.
Chronic liver disease including NAFLD or liver cirrhosis assessed via abdominal ultraso-
nography or liver biopsy was reported to be associated with low bone mass [10–12]. However,
abdominal ultrasonography often lacks the sensitivity required to identify early steatosis, and
liver biopsy is an invasive procedure; performing liver biopsies on all at-risk individuals is not
feasible in clinical practice [13]. To overcome this limitation, liver transient elastography (TE,
Fibroscan) has been widely used as a non-invasive, easy, and rapid method for quantification
and evaluation of liver fibrosis or steatosis [14,15]. Recently, several studies reported that liver
stiffness measurement by using TE was a clinically useful noninvasive alternative to liver
biopsy, providing a numerical value and well reflecting liver fibrosis [16,17]. In addition,
simultaneous evaluation of hepatic steatosis by using the controlled attenuation parameter
(CAP) based on TE has proven to be efficient in differentiating steatosis grades [18]. Therefore,
in this present study, we identified patients with NAFLD and measured liver stiffness by using
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non-invasive TE in order to investigate the association between liver fibrosis and BMD in indi-
viduals with NAFLD.
Materials and methods
The study population
This study retrospectively included 440 asymptomatic individuals who underwent evaluation
via both dual-energy X-ray absorptiometry (DXA) and TE for a health check-up at the univer-
sity-affiliated Severance Hospital, Seoul, Republic of Korea, between February 2012 and
December 2014. As shown in Fig 1, exclusion criteria for this study were as follows: women
aged50 years (n = 57) to exclude pre-menopausal women, any etiological markers for
chronic liver disease including positive serologic markers for hepatitis B virus (n = 53) and
hepatitis C virus (n = 17), autoimmune hepatitis (n = 5), history of alcohol consumption >210
g/week for men and 140 g/week for women (n = 7), presence of primary biliary cirrhosis
Fig 1. Study subject disposition.
https://doi.org/10.1371/journal.pone.0182202.g001
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(n = 3), presence of right-sided heart failure (n = 4), prior history of malignancy (n = 9), invalid
liver stiffness value (n = 12), and sequential data from identical subjects (n = 42). Ultimately, a
total of 231 individuals were analyzed in this study. Informed consent for this study was not
required because the database was only accessed for purpose of analysis without personal
information. The protocol of this study was approved by the Institutional Review Board (IRB
No. 4-2015-0285) of Severance Hospital.
Clinical and laboratory variables
Body mass index (BMI) was defined as weight divided by the square of the height (kg/m2).
Blood samples were obtained after an 8-hour fast. Routine serum chemistry determinations
including plasma glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT),
calcium, and albumin were performed using standard automated laboratory techniques;
25-hydroxyvitamin D was assayed using D3-radioimmunoassay-coated tubes (Biosource,
Nivelles, Belgium). Glycated hemoglobin (HbA1c) was measured as previously described [19].
Plasma total cholesterol, triglycerides (TG), and high-density lipoprotein (HDL) cholesterol
levels were measured using a Hitachi 7600 Auto Analyzer (Hitachi Instruments Service,
Tokyo, Japan). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald
equation (LDL cholesterol [mg/dL] = total cholesterol [mg/dL]–HDL cholesterol [mg/dL]
− TG [mg/dL] / 5) [20].
Measurement of bone mineral density via DXA
Areal BMD was measured for the lumbar spine from L1 to L4, the femoral neck, and the total
hip in all subjects using DXA (Hologic Delphi A version 12.6, Hologic, Waltham, MA, USA).
Results are expressed as BMD (g/cm2) and T-scores. T-scores were calculated using reference
values from the National Health and Nutrition Examination Survey (NHANES) III [21]. Oste-
oporosis was defined as a T-score of less than or equal to –2.5 at least one out of the three skele-
tal sites (lumbar spine, femur neck, or total hip) while osteopenia was between –1.0 and –2.5 at
any one of these three sites, according to World Health Organization criteria [22].
Measurement of liver stiffness and controlled attenuation parameter
using TE
The measurement of liver stiffness (LS), CAP, and variability using TE was assessed as
described previously [23–25]. Transient elastography (fibroscan) was performed by one
experienced technician (more than 10,000 examinations), who was blind to patients’ clinical
data [25]. The results are described as decibels per meter (dB/m) and kilopascals (kPa) for
CAP and LS, respectively. The interquartile range (IQR) was assessed as an index of the intrin-
sic variability of LS values corresponding to the interval of LS values containing 50% of the
valid measurements between the 25th and 75th percentiles. Only cases with at least 10 vali-
dated acquisitions, a success rate of at least 60%, and a ratio of the IQR of LS to median values
(IQR/MLS) less than 0.3 were considered reliable [26]. The CAP was determined only when
LS measurement was reliable for the simultaneous signals at the same volume of liver paren-
chyma, and the final CAP value was the median of individual CAP values using the same valid
measurements [27]. In this study, a cut-off point of CAP250 dB/m was defined as nonalco-
holic fatty liver disease (NAFLD), and a cut-off point of LS>7.0 kPa was defined as significant
liver fibrosis assessed via TE, based on previous studies [27,28].
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Statistical analyses
All continuous variables are expressed as mean ± standard deviation, and categorical variables
are expressed as proportions. Differences were analyzed using independent Student’s t-tests or
Mann-Whitney U-tests for continuous variables and chi-square tests or Fisher’s exact tests for
categorical variables. Pearson’s correlation analysis was performed to examine the relation-
ships between BMD and metabolic variables. A multivariate linear regression analysis was per-
formed to determine the independent relationships of the studied variables, and standardized
β was represented as the coefficient β. The odds ratios (ORs) and 95% confidence intervals
(CIs) for significant liver fibrosis associated with overall osteopenia and osteoporosis were cal-
culated using multivariate logistic regression analysis. In multivariate analysis, model 1 was a
crude form and model 2 adjusted for age, sex, and BMI. In model 3, we adjusted for model 2
covariates in addition to fasting plasma glucose. Model 4 adjusted for age, sex, BMI, fasting
plasma glucose, ALT, HDL cholesterol, and CAP. A P value of<0.05 was considered to be sta-
tistically significant. Statistical analyses were performed using PASW Statistics software, ver-
sion 20.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study population
The baseline clinical and laboratory characteristics of the total study population are shown in
Table 1. For all subjects (n = 231), the mean age was 61.8 ± 8.4 years, and 160 (69.3%) were
women. The mean BMI was 24.5 ± 3.3 kg/m2. A total 18.6% of patients had a history of diabe-
tes (n = 43), and 15.4% had osteoporosis (n = 36). Of these 231 subjects, 129 (55.8%) had
NAFLD. The subjects with NAFLD had significantly increased BMI, higher levels of HbA1c,
fasting plasma glucose, ALT, albumin, TG, lower levels of HDL, and a higher proportion of
significant liver fibrosis relative to subjects without NAFLD. In contrast, BMD at the lumbar
spine, femur neck, or total hip showed similar values between subjects with and without
NAFLD.
The characteristics of subjects with NAFLD according to significant liver fibrosis status are
described in Table 2. Levels of serum AST, ALT, triglycerides, and CAP were significantly
higher in subjects with significant liver fibrosis than in those without significant fibrosis, while
lumbar spine, femur neck, and total hip BMDs were markedly lower. The prevalence of overall
osteopenia and osteoporosis in NAFLD patients with significant fibrosis was significantly
higher than in those without significant fibrosis (P = 0.010). Fig 2 displays BMDs at lumbar
spine, femur neck, and total hip among subjects with normal, NAFLD, and NAFLD with sig-
nificant fibrosis. BMDs were similar between normal and NAFLD groups but, patients with
NAFLD with significant fibrosis showed significant lower BMDs, compared to normal or
NAFLD group (Ps<0.005).
Associations between BMD and metabolic measures
To assess the relationship between BMD and metabolic variables in patients with NAFLD, a
univariate analysis was performed (Table 3). BMDs at all sites revealed strong inverse correla-
tions with significant liver fibrosis (lumbar spine, r = –0.19, P = 0.032; femur neck, r = –0.19,
P = 0.034; total hip BMD, r = –0.21, P = 0.016), while no significant association was found
between liver steatosis and BMD.
Significant liver fibrosis assessed by transient elastography and low BMD
PLOS ONE | https://doi.org/10.1371/journal.pone.0182202 July 31, 2017 5 / 14
Multivariate analysis
Among patients with NAFLD, multivariate linear regression analyses were performed to inves-
tigate the independent association between BMD and significant liver fibrosis (Table 4). After
adjustment for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP (repre-
senting liver steatosis), significant liver fibrosis was independently associated with BMDs at
the femur neck (β = –0.18, P = 0.039) and total hip (β = –0.21, P = 0.005) in patients with
NAFLD.
Table 1. Characteristics of study participants.
Variables All (n = 231) Subjects without NAFLD (n = 102, 44.2%) Subjects with NAFLD (n = 129, 55.8%) P value
Age (years) 61.8 ± 8.4 62.0 ± 8.8 61.6 ± 8.0 0.694
Sex (women), n (%) 160 (69.3) 70 (68.6) 90 (69.8) 0.482
BMI (kg/m2) 24.5 ± 3.3 22.9 ± 3.0 25.8 ± 3.1 <0.001
Diabetes mellitus, n (%) 43 (18.6) 17 (16.7) 26 (20.2) 0.308
Statin user, n (%) 72 (31.2) 24 (23.5) 48 (37.2) 0.018
Osteopenia, n (%) 109 (47.2) 48 (47.1) 61 (47.3) 0.973
Osteoporosis, n (%) 36 (15.6) 17 (16.7) 19 (14.7) 0.411
Overall osteopenia and osteoporosis 145 (62.8) 65 (63.7) 80 (62.0) 0.891
Laboratory variables
HbA1c (%) 6.3 ± 1.0 6.1 ± 0.7 6.5 ± 1.2 0.019
Fasting plasma glucose (mg/dL) 103.2 ± 21.4 100.0 ± 18.7 105.9 ± 23.2 0.036
AST (IU/L) 33.6 ± 31.4 34.6 ± 40.4 32.8 ± 21.9 0.660
ALT (IU/L) 31.8 ± 28.9 26.7 ± 26.6 35.7 ± 30.0 0.018
Calcium (mg/dL) 9.1 ± 0.5 9.1 ± 0.4 9.1 ± 0.5 0.606
Albumin (mg/dL) 4.2 ± 0.4 4.1 ± 0.5 4.2 ± 0.4 0.020
25-hydroxy vitamin D (IU) 22.7 ± 10.9 22.6 ± 10.4 23.0 ± 11.2 0.830
Total cholesterol (mg/dL) 174.8 ± 42.9 176.9 ± 49.3 173.1 ± 37.2 0.504
TG (mg/dL) 123.7 ± 69.8 105.8 ± 61.1 136.6 ± 73.0 0.001
HDL cholesterol (mg/dL) 49.2 ± 14.4 52.7 ± 17.0 46.5 ± 11.3 0.002
LDL cholesterol (mg/dL) 101.1 ± 32.3 103.9 ± 35.9 98.9 ± 29.1 0.278
DXA scan
Lumbar spine BMD (g/cm2) 0.910 ± 0.174 0.896 ± 0.172 0.921 ± 0.176 0.280
Lumbar spine T-score -0.87 ± 1.43 -0.97 ± 1.37 -0.79 ± 1.48 0.335
Femur neck BMD (g/cm2) 0.693 ± 0.124 0.685 ± 0.120 0.700 ± 0.128 0.365
Femur neck T-score -1.11 ± 1.05 -1.19 ± 1.02 -1.05 ± 1.08 0.322
Total hip BMD (g/cm2) 0.838 ± 0.146 0.827 ± 0.139 0.847 ± 0.151 0.320
Total hip T-score -0.35 ± 1.02 -0.45 ± 0.97 -0.27 ± 1.07 0.204
Transient elastography
CAP (dB/m) 262.9 ± 51.2 217.0 ± 24.0 299.2 ± 35.3 <0.001
IQRCAP (dB/m) 28.8 ± 13.0 30.7 ± 12.5 27.3 ± 13.3 0.056
Liver stiffness value (kPa) 5.70 ± 4.15 5.62 ± 4.94 5.76 ± 3.4 0.810
IQRLS (kPa) 0.73 ± 0.62 0.72 ± 0.70 0.74 ± 0.55 0.754
IQR/medianLS 0.13 ± 0.05 0.13 ± 0.05 0.13 ± 0.06 0.774
Significant liver fibrosis (>7 kPa), n, % 38 (16.5) 10 (9.8) 28 (21.7) 0.011
Values are presented as the mean ± standard deviation (SD) or n (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMD, bone
mineral density; BMI, body mass index; CAP, controlled attenuation parameter; DXA, dual-energy X-ray absorptiometry; HDL, high density lipoprotein; IQR,
interquartile range; LDL, low density lipoprotein; NAFLD, nonalcoholic fatty liver disease; TG, triglycerides.
https://doi.org/10.1371/journal.pone.0182202.t001
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Table 2. Comparison between subjects with and without significant liver fibrosis (LS >7 kPa) among subjects with NAFLD (n = 129).
Without significant fibrosis (LS value7 kPa,
n = 101)
With significant fibrosis (LS value >7 kPa,
n = 28)
P value
Age (years) 61.9 ± 7.4 60.6 ± 10.1 0.775
Sex (women), n (%) 67 (66.3) 23 (82.1) 0.081
BMI (kg/m2) 25.5 ± 3.0 26.6 ± 3.3 0.131
Diabetes mellitus, n (%) 32 (16.6) 7 (25.0) 0.161
Statin, n (%) 41 (40.6) 7 (25.0) 0.097
Osteopenia, n (%) 45 (44.6) 16 (57.1) 0.167
Osteoporosis, n (%) 12 (11.9) 7 (25.0) 0.127
Overall osteopenia and osteoporosis,
n (%)
57 (56.4) 23 (82.1) 0.010
HbA1c (%) 6.4 ± 1.2 6.6 ± 1.2 0.253
Fasting plasma glucose (mg/dL) 106.5 ± 24.3 103.6 ± 18.5 0.955
AST (IU/L) 29.0 ± 18.1 46.3 ± 28.7 <0.001
ALT (IU/L) 31.1 ± 27.1 52.5 ± 34.6 <0.001
Calcium (mg/dL) 9.0 ± 0.5 9.3 ± 0.5 0.011
Albumin (mg/dL) 4.2 ± 0.3 4.4 ± 0.6 0.006
25-hydroxy vitamin D (IU) 22.6 ± 11.2 24.2 ± 11.3 0.527
Total cholesterol (mg/dL) 174.0 ± 38.6 169.8 ± 32.1 0.491
TG (mg/dL) 129.3 ± 68.2 162.8 ± 84.2 0.022
HDL cholesterol (mg/dL) 47.3 ± 11.9 43.7 ± 8.5 0.256
LDL cholesterol (mg/dL) 98.9 ± 30.7 98.8 ± 22.7 0.997
Lumbar spine BMD (g/cm2) 0.938 ± 0.180 0.858 ± 0.145 0.045
Lumbar spine T-score -0.64 ± 1.51 -1.32 ± 1.26 0.045
Femur neck BMD (g/cm2) 0.712 ± 0.130 0.655 ± 0.111 0.048
Femur neck T-score -0.96 ± 1.09 -1.38 ± 1.00 0.100
Total hip BMD (g/cm2) 0.864 ± 0.151 0.786 ± 0.137 0.023
Total hip T-score -0.16 ± 1.04 -0.69 ± 1.07 0.037
CAP (dB/m) 295.7 ± 34.0 312.0 ± 37.7 0.042
Liver stiffness value (kPa) 4.65 ± 1.13 9.74 ± 5.43 <0.001
Values are presented as the mean ± standard deviation (SD) or n (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMD, bone
mineral density; BMI, body mass index; CAP, controlled attenuation parameter; HDL, high density lipoprotein; LDL, low density lipoprotein; LS, liver
stiffness; NAFLD, nonalcoholic fatty liver disease; TG, triglycerides.
https://doi.org/10.1371/journal.pone.0182202.t002
Fig 2. Bone mineral density at lumbar spine, femur neck, and total hip among subject with normal,
NAFLD, and NAFLD with significant fibrosis. NAFLD, non-alcoholic fatty liver disease.
https://doi.org/10.1371/journal.pone.0182202.g002
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Multivariate logistic regression analyses were performed on significant liver fibrosis for
overall osteopenia and osteoporosis in patients with NAFLD (Table 5). In the Model 1, the
presence of significant liver fibrosis was associated with as increased risk for overall osteopenia
and osteoporosis with an odds ratio of 3.55 (95% CI = 1.25–10.09). Subjects having NAFLD
with significant fibrosis showed an independent association with overall osteopenia and osteo-
porosis (OR = 4.10, 95% CI = 1.02–16.45) in the model 5 adjusted for age, sex, BMI, fasting
plasma glucose, ALT, HDL cholesterol, and CAP, compared to those having NAFLD without
significant fibrosis.
Table 3. Factors associated with bone mineral density in subjects with NAFLD (n = 129).
Variables Lumbar spine (g/cm2) Femur neck (g/cm2) Total hip (g/cm2)
r P value r P value r P value
Age (years) 0.05 0.575 -0.20 0.022 -0.15 0.084
Sex (male = 0, female = 1) -0.44 <0.001 -0.48 <0.001 -0.46 <0.001
BMI (kg/m2) 0.21 0.019 0.31 <0.001 0.31 <0.001
Diabetes mellitus 0.04 0.643 0.138 0.119 0.135 0.126
HbA1c (%) 0.01 0.911 0.03 0.800 0.06 0.574
Fasting blood glucose (mg/dL) 0.22 0.013 0.21 0.021 0.22 0.014
AST (IU/L) -0.24 0.006 -0.07 0.421 -0.09 0.306
ALT (IU/L) -0.19 0.029 0.01 0.903 -0.01 0.977
Calcium (mg/dL) -0.05 0.449 0.07 0.328 0.04 0.596
Albumin (mg/dL) -0.16 0.068 0.03 0.760 -0.05 0.586
25-hydroxy vitamin D (IU) -0.19 0.075 -0.17 0.110 -0.12 0.242
Total cholesterol (mg/dL) -0.12 0.182 -0.01 0.968 -0.01 0.918
TG (mg/dL) -0.04 0.684 0.11 0.217 0.09 0.342
HDL cholesterol (mg/dL) -0.22 0.015 -0.19 0.046 -0.15 0.104
LDL cholesterol (mg/dL) -0.09 0.334 -0.05 0.613 -0.07 0.437
CAP (dB/m) -0.08 0.343 0.02 0.846 0.05 0.605
aLiver stiffness value (kPa) -0.03 0.745 -0.06 0.469 -0.07 0.457
Significant liver fibrosis (LS > 7kPa) -0.19 0.032 -0.19 0.034 -0.21 0.016
alog-transformed.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation
parameter; HDL, high density lipoprotein; LDL, low density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease; TG, triglycerides.
https://doi.org/10.1371/journal.pone.0182202.t003
Table 4. Multivariate linear regression analysis of the correlation between BMD and significant liver fibrosis in subjects with NAFLD (n = 129).
Lumbar spine BMD (g/cm2) Femur neck BMD (g/cm2) Total hip BMD (g/cm2)
R2 β P value R2 β P value R2 β P value
Model 1 0.028 -0.19 0.032 0.027 -0.19 0.034 0.037 -0.21 0.016
Model 2 0.214 -0.15 0.064 0.308 -0.17 0.025 0.288 -0.21 0.007
Model 3 0.230 -0.12 0.163 0.344 -0.18 0.020 0.332 -0.23 0.003
Model 4 0.189 -0.10 0.312 0.320 -0.20 0.028 0.369 -0.23 0.013
Model 1: crude; Model 2: adjusted for age, sex, BMI; Model 3: adjusted for age, sex, BMI, fasting plasma glucose; Model 4: adjusted for age, sex, BMI,
fasting plasma glucose, ALT, HDL cholesterol, CAP. ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled
attenuation parameter; HDL, high density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease.
https://doi.org/10.1371/journal.pone.0182202.t004
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Discussion
In the present study, we firstly applied liver TE (Fibroscan), a noninvasive tool for showing
numerical values for liver steatosis based on CAP, and liver fibrosis based on LS, in order to
investigate the association between liver fibrosis and osteopenia in patients with non-alcoholic
fatty liver disease (NAFLD). We showed that BMD was reduced in subjects with significant
liver fibrosis (LS >7 kPa) and that the presence of significant liver fibrosis was correlated with
low BMDs at all sites, including the lumbar spine, femur neck, and total hip in patients with
NAFLD. After adjustment for all confounding variables, significant liver fibrosis remained an
independent determinant of low BMD at the femur among NAFLD patients. Furthermore,
subjects having NAFLD with significant fibrosis were significantly associated with overall
osteopenia and osteoporosis compared to those having NAFLD without significant fibrosis.
Liver fibrosis is the result of a massive accumulation of extracellular matrix and scar forma-
tion, eventually resulting in cirrhosis [29]. Osteoporosis is a common complication of liver cir-
rhosis, which is a progressive and severe chronic liver disease, and up to about 40% of patients
with chronic liver disease may be at risk of bone fracture [7,30]. Previously, children with
NASH had a significantly lower BMD than those with NAFLD who did not have NASH [31].
In addition, as suggestive of NASH, subjects with NAFLD showing elevated serum ALT and
C-reactive protein (CRP) were associated with low BMD [32]. Xia et al. reported that there was
a synergistic worsening of the BMDs in subjects with both NAFLD and elevated serum ALT
[33]. However, the relationship of liver fibrosis and BMD in asymptomatic subjects with
NAFLD is poorly understood. In this study, the significant fibrosis in NAFLD, indicating pro-
gression of inflammation in liver steatosis, was markedly associated with low BMD. The asso-
ciation between NAFLD and osteopenia also remains controversial. NAFLD was associated
with low lumbar BMD and osteoporotic fractures in children and adults in several studies
[6,11,34]. Meanwhile, in men yet not in women, the presence of NAFLD was associated with
osteoporotic fractures in another study [11], and simple steatosis of the liver did not affect
BMD [32]. In this present study, the presence or absence of NAFLD did not significantly affect
BMD values. However, the multivariate regression analysis revealed that significant liver fibro-
sis, not CAP, which indicated the degree of liver steatosis, was an independent determinant of
low BMD. Therefore, we suggest that NAFLD subjects with significant liver fibrosis should be
concerned about the risk of low BMD.
Interestingly, the presence of significant liver fibrosis remained an independent risk factor
for low BMD only at the femur after adjustment of all confounding factors. In a crude model
(model 1), the presence of significant liver fibrosis was an independent factor for spinal BMD;
Table 5. Multivariate logistic regression analysis of significant liver fibrosis for overall osteopenia
and osteoporosis in subjects with NAFLD (n = 129).
Variables OR 95% CI P value
Model 1 3.55 1.25–10.09 0.017
Model 2 4.01 1.21–13.31 0.023
Model 3 3.67 1.06–12.70 0.040
Model 4 4.10 1.02–16.45 0.047
Model 1: crude; Model 2: adjusted for age, sex, BMI; Model 3: adjusted for age, sex, BMI, fasting plasma
glucose; Model 4: adjusted for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP. ALT,
alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation
parameter; HDL, high density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease; OR,
odds ratio.
https://doi.org/10.1371/journal.pone.0182202.t005
Significant liver fibrosis assessed by transient elastography and low BMD
PLOS ONE | https://doi.org/10.1371/journal.pone.0182202 July 31, 2017 9 / 14
however, it was not an independent factor after adjusting for confounding factors. We were
unable to find an explanation for these discrepancies. However, in this context, previous stud-
ies showed that loss of BMD at the femur was greater than that at the lumbar spine in patients
who underwent liver transplantation [35] as well as in those with alcoholic liver cirrhosis [36].
Compared to the controls, the thickness of the cortex was significantly thinner in patients with
significant fibrosis, which might be explained by enhanced endocortical bone resorption [36].
Further study is required to explore the mechanism of preferential bone loss in cortical bone
in patients with liver fibrosis.
The pathophysiology linking liver fibrosis to low bone mass has not been well established
due to complex and multifactorial mechanisms. Pathogenic mediators, including fibronectin,
IGF-1, the RANKL/OPG system, and several cytokines, such as TNF-α and the IL-6 family,
have been suggested to play important roles in the pathogenesis of bone loss in chronic liver
disease [30,37]. Lipotoxicity, reactive oxidative stress, activated hepatic macrophages releasing
pro-inflammatory cytokines, and hepatocyte-derived extracellular vesicles released during
lipotoxicity can modulate hepatic inflammatory/immune system leading to hepatic injury,
NASH, and fibrosis [38,39]. In addition, hepatic inflammation and fibrosis are also linked to
adipose inflammation and insulin resistance, through a release of inflammatory mediators
such as TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1) from adipose tissue
[40,41]. Therefore, our results showing a strong association between low BMD and significant
liver fibrosis in NAFLD may be partly explained by the development of osteopenia through the
systemic inflammation and insulin resistance observed in this disorder. Vitamin D deficiency
may also contribute to worsening bone health in chronic liver disease [30,42]. Indeed, 92% of
patients with chronic liver disease revealed vitamin D deficiency, although most had chronic
hepatitis C [43]. Low vitamin D and high parathyroid hormone levels were independently
associated with the presence of NAFLD [44]. In contrast, Goral et al. reported normal vitamin
D levels in patients with liver cirrhosis [45], and no direct relationship between vitamin D lev-
els and the severity of osteoporosis was detected [7,46]. Likewise, the current study demon-
strated no significant difference in vitamin D levels according to the presence of significant
liver fibrosis, and no significant correlation was found between BMD and the level of vitamin
D. Taken together, more studies are required to elucidate the mechanism of liver fibrosis–asso-
ciated bone loss.
The present study has several strengths. To our knowledge, this is the first study to investi-
gate the association between BMD and liver fibrosis assessed via liver TE in patients with
NAFLD. Therefore, we could measure liver fibrosis or steatosis using TE, and we were able to
easily identify subjects who had liver steatosis and verify significant liver fibrosis without inva-
sive investigation. Secondly, we excluded subjects with autoimmune hepatitis, chronic hepati-
tis B, chronic hepatitis C, alcoholic hepatitis, drug-induced hepatitis, primary biliary cirrhosis,
right-sided heart failure, or a history of malignancy, which could have yielded LS values for
fibrosis with a different distribution when assessed via TE [47,48].
The current study also has limitations. It was based on a cross-sectional study design, which
made it difficult to determine a causal relationship between liver fibrosis and low BMD. More-
over, although liver TE has been used to assess fibrosis and steatosis, liver biopsies were not
conducted in this study as a reference standard for diagnosis and assessment of the degree of
fibrosis or steatosis. However, recent studies revealed that liver TE measurement is well corre-
lated with the degree of fibrosis or steatosis assessed via biopsy [14,49]. There are also some
issues that have to be taken into account when using TE. When interpreting results of TE, fac-
tors including obesity, presence of liver steatosis, and elevated levels of serum ALT may affect
the results [50–52]. Also, as a substantial interoperator variability is presented, liver TE mea-
surement made by the same operator with a high number of examinations for operator
Significant liver fibrosis assessed by transient elastography and low BMD
PLOS ONE | https://doi.org/10.1371/journal.pone.0182202 July 31, 2017 10 / 14
experience may reduce the variation [53,54]. In the present study, liver TE was performed by
a single experienced operator that may enhance the reliability of CAP and liver stiffness.
Additionally, we did not assess bone turnover markers. Previous studies suggested that
decreased bone formation or increased bone resorption affect the pathogenesis of hepatic
osteodystrophy [7,10,55]. Moreover, factors may have a link with bone mineralization includ-
ing use of hormonal replacement therapy, Homeostasis Model Assessment of Insulin Resis-
tance (HOMA-IR) index in relation to insulin resistance, or CRP as a marker of systemic
inflammation were not accessed in the study due to lack of these variables [56–58].
Conclusions
In conclusion, we confirmed that the presence of significant liver fibrosis assessed via liver TE
(Fibroscan) was strongly associated with overall osteopenia and osteoporosis in asymptomatic
individuals with NAFLD. Importantly, the presence of significant liver fibrosis was an inde-
pendent determinant for low BMD in patients with NAFLD. Altogether, these finding indi-
cated that the progression of hepatic inflammation and fibrosis might be closely related to
bone loss. As advanced hepatic osteodystrophy is difficult to treat and could increase the bur-
den on society with adverse long-term prognosis and increased morbidity, early screening and
assessment for the risk of bone loss, even in asymptomatic NAFLD patients with significant
liver fibrosis, must be considered. Furthermore, prospective studies are warranted to confirm
the causative relationship between the presence of significant fibrosis and the development of
bone loss.
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